(CDAX, Software/IT)



		Value Indicators:	EUR	Share data:		Description:				
Hold		DCF:	21.67	Bloomberg:	M3V GR	A leading supplier of softw	are for			
				Reuters:	M3VG	visual-based medical equi	pment			
EUR 22.00	(EUR 21.00)			ISIN:	DE000A0LBFE4					
		Market Snapshot:	EUR m	Shareholders:		Risk Profile (WRe):	2015e			
		Market cap:	47.0	Freefloat	23.5 %	Beta:	1.8			
Price	EUR 25.80	No. of shares (m):	1.8	Varian Medical Syste	ms 73.5 %	Price / Book:	1.1 x			
Downside	-14.7 %	EV:	20.8	Oppenheim Asset Ma	anag. 3.0 %	Equity Ratio:	74 %			
	=	Freefloat MC:	11.0							
		Ø Trad. Vol. (30d):	3.25 th							

Benefiting longer from Hologic; Figures surprisingly strong

Stated Figure	es Q4/2	015:							Comment on Figures:
FY End: 31.12. in EUR m	Q4 15	Q4 15e	Q4 14	уоу	15	15e	14	уоу	 Sales increased in 2015 following positive development of exchange rates. FX effects explain EUR 2.3m of top-line growth.
Sales	4.1	2.8	3.4	19 %	16.0	14.7	13.1	22 %	 Furthermore, sales include a EUR 0.5m effect in regard to service
EBITDA	1.3	0.7	1.2	7 %	6.4	5.8	5.6	15 %	development work contributed to Hologic's new software, PRIMA.
Margin	31.8 %	23.7 %	35.3 %		40.0 %	39.2 %	42.7 %		 Adjusted for both effects, sales were almost stable with a slight inc
EBIT	0.8	0.1	0.7	15 %	4.5	3.7	3.9	15 %	of EUR 0.1m yoy.
Margin	20.8 %	3.1 %	21.6 %		27.9 %	25.2 %	29.7 %		
EPS	2.12	0.22	0.15	1313 %	3.76	1.84	2.16	74 %	

MeVis has released final figures for 2015 which were better than expected. While the operating business was almost flat, FX effects led to a sales increase of roughly EUR 2.3m. In light of changes in the cooperation with Hologic, MeVis booked service and development revenues in 2015 (EUR 0.5m). Currently, Hologic is still the main customer accounting for more than 75% of sales (WRe). These revenues are mainly achieved with the supply of software and licenses as well as maintenance.

MeVis has already started to develop state of the art software for Hologic. MeVis has become a single-source software supplier for Hologic in the segment of digital mammography. While MeVis is currently benefiting from sales of licenses, in the future (2018e and beyond) the company will participate in revenue, based on Hologic's sales prices of the newly-developed software. As a result of both the transformed business model and IFRS regulations, these service and development revenues have to be booked as long-term receivables. Therefore accounts receivable is expected to increase in the upcoming years. EUR 0.9m were already capitalised in 2015.


We have updated our assumptions and rolled over the DCF model. Backed by the secure dividend payment of EUR 0.95 per share (paid by Varian due to the profit and loss transfer agreement with VMS Deutschland Holdings), which represents a yield of almost 4% p.a. the recommendation is being kept unchanged with a slightly increased price target of EUR 22. Hold.

Changes in E	stimates:						Comment on Changes:
FY End: 31.12. in EUR m	2016e (old)	+ / -	2017e (old)	+ / -	2018e (old)	+ / -	Hologic is expected to take longer than initially planned, mainly be
Sales	12.0	20.3 %	9.7	43.6 %	9.4	14.4 %	Hologic intends to use another technological platform than mentio
EBITDA	4.0	15.2 %	1.8	123.9 %	1.8	-17.9 %	2014. Hologic's new requirement was brought to MeVis at the end
EBIT	2.3	8.5 %	0.4	445.5 %	0.5	-61.8 %	2016. Taking this news-flow into account, it is assumed that sale
EBT	2.4	8.1 %	0.5	360.5 %	0.6	-51.1 %	earnings will remain stable until end of 2017. The shift of the bu
Net income	2.1	22.9 %	0.5	423.3 %	0.5	-44.4 %	model should become visible in 2018 and beyond.

28 -		FY End: 31.12. in EUR m	CAGR (15-18e)	2012	2013	2014	2015	2016e	2017e	2018e
26 - 24 - 23 -	AMARA	Sales	-12.6 %	13.3	14.6	13.1	16.0	14.4	13.9	10.7
23 Montheam		Change Sales yoy		-2.4 %	9.4 %	-10.3 %	22.3 %	-9.9 %	-3.9 %	-22.9 %
22 atm M		Gross profit margin		114.1 %	104.9 %	104.3 %	96.2 %	95.0 %	95.0 %	95.0 %
		EBITDA	-38.8 %	6.0	6.1	5.6	6.4	4.6	4.0	1.5
20 WY) MY 4M4		Margin		44.6 %	41.8 %	42.7 %	40.0 %	31.9 %	28.7 %	13.7 %
19 Vin v	· · · · · · ·	EBIT	-65.6 %	3.0	4.1	3.9	4.5	2.5	2.3	0.2
18. I W. "	ኒሲ ፈሳጦን 🗌	Margin		22.3 %	27.8 %	29.7 %	27.9 %	17.4 %	16.7 %	1.7 %
17 -	· Vi	Net income	-65.3 %	2.2	3.7	3.7	6.7	2.6	2.4	0.3
06/16 07/16 08/16 11/16 01/16	6 03/16	EPS	-65.1 %	1.26	2.15	2.16	3.76	1.46	1.35	0.16
MeVis Medical Solutions CDAX (EPS adj.	-65.1 %	1.26	2.15	2.16	3.76	1.46	1.35	0.16
	ne manaco)	DPS	0.0 %	0.00	0.00	0.04	0.95	0.95	0.95	0.95
Rel. Performance vs CDA	X :	Dividend Yield		n.a.	n.a.	0.3 %	4.4 %	3.7 %	3.7 %	3.7 %
		FCFPS		1.56	3.39	1.90	3.61	2.48	2.01	0.64
1 month:	1.6 %	FCF / Market cap		23.9 %	26.4 %	12.2 %	16.8 %	9.4 %	7.7 %	2.4 %
6 months:	17.1 %	EV / Sales		0.2 x	0.8 x	1.3 x	0.8 x	1.4 x	1.4 x	1.9 x
Year to date:	11.9 %	EV / EBITDA		0.4 x	2.0 x	3.1 x	2.1 x	4.5 x	4.8 x	13.6 x
Trailing 12 months:	29.8 %	EV / EBIT		0.9 x	3.0 x	4.5 x	3.0 x	8.3 x	8.3 x	110.1 x
· · • • • • • • • • • • • • • • • • • •		P/E		5.2 x	6.0 x	7.2 x	5.7 x	17.7 x	19.1 x	162.4 x
Company events:		P / E adj.		5.2 x	6.0 x	7.2 x	5.7 x	17.7 x	19.1 x	162.4 x
24.05.16	Q1	FCF Yield Potential		123.0 %	35.5 %	15.2 %	58.9 %	22.1 %	20.8 %	6.3 %
07.06.16	AGM	Net Debt		-8.7	-9.8	-9.3	-25.0	-26.1	-27.8	-27.3
23.08.16	Q2	ROCE (NOPAT)		17.0 %	25.4 %	15.5 %	40.9 %	30.8 %	32.5 %	2.9 %
17.11.16	Q3	Guidance:	2016e: Sales	EUR 14.5-15	im; EBIT EUI	R 2.5-3m				
Analyst										

Harald Hof hhof@warburg-research.com +49 40 309537-125






Company Background

- The origin of MeVis Medical Solutions AG, which was set up in 1998, dates back to 1992, when the CeVis (Center for Complex Systems and Visualization) was founded at the University of Bremen.
- The public company was founded with the aim of developing commercially successful disease-oriented products based on successes in scientific research and to market these.
- Since its foundation, MeVis has been active in the area of computer-aided, image-based medical diagnostics and therapy.
- MeVis has successfully risen to become a globally-leading provider of software solutions for medical imaging. This development is mainly based on the success in the area of digital mammography.
- Together with products by Hologic and Siemens, MeVis's solutions dominate this segment today. Furthermore, MeVis has a broad portfolio of new products.

Competitive Quality

- MeVis follows a strategy of early market presence in the new areas of image-based medical technology. In focus here are mass market products.
- The ability to be an early market entrant differentiates MeVis from competitors.
- MeVis maintains long-term and interdisciplinary cooperation agreements with more than 100 hospitals and leading R&D centres in Germany, Europe, the US and Asia.
- MeVis fosters partnerships with the globally leading medical technology OEMs, for instance Siemens and Hologic.





DCF model														
	Detailed	d forecas	t period				Т	ransition	al period					Term. Value
Figures in EUR m	2015	2016e	2017e	2018e	2019e	2020e	2021e	2022e	2023e	2024e	2025e	2026e	2027e	
Sales	16.0	14.4	13.9	10.7	10.3	7.9	7.2	6.8	6.6	6.7	6.9	7.1	7.3	
Sales change	22.3 %	-9.9 %	-3.9 %	-22.9 %	-3.9 %	-22.9 %	-9.5 %	-5.5 %	-3.0 %	2.3 %	2.5 %	2.5 %	2.5 %	2.5 %
EBIT	4.5	2.5	2.3	0.2	1.7	0.1	-0.3	-0.2	-0.2	0.2	1.4	1.6	1.6	
EBIT-margin	27.9 %	17.4 %	16.7 %	1.7 %	16.7 %	1.7 %	-3.7 %	-3.3 %	-2.6 %	3.3 %	20.0 %	22.0 %	22.0 %	
Tax rate (EBT)	-36.0 %	0.0 %	0.0 %	0.0 %	12.0 %	12.0 %	12.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	
NOPAT	6.1	2.5	2.3	0.2	1.5	0.1	-0.2	-0.2	-0.1	0.2	1.0	1.1	1.1	
Depreciation	1.9	2.1	1.7	1.3	1.4	1.0	0.9	0.8	0.8	0.7	0.8	0.7	0.7	
in % of Sales	12.1 %	14.5 %	12.0 %	12.0 %	14.0 %	13.0 %	13.0 %	12.0 %	12.0 %	11.0 %	11.0 %	10.0 %	9.0 %	
Changes in provisions	0.6	0.0	0.0	0.0	-0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in Liquidity from														
- Working Capital	0.2	-0.2	-0.2	-0.4	0.0	-0.4	-0.1	-0.1	0.0	0.0	0.0	0.0	0.0	
- Capex	0.1	0.5	0.7	0.8	1.5	1.0	0.8	0.7	0.7	0.7	0.7	0.6	0.6	
Capex in % of Sales	0.7 %	3.4 %	4.9 %	7.6 %	15.0 %	13.0 %	11.0 %	10.0 %	10.0 %	10.0 %	10.0 %	8.0 %	8.0 %	
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	8.4	4.3	3.5	1.1	0.8	0.5	0.0	0.0	0.0	0.2	1.0	1.2	1.2	1
PV of FCF	0.0	4.1	3.0	0.8	0.5	0.3	0.0	0.0	0.0	0.1	0.4	0.4	0.3	3
share of PVs		57.71 %						17.14	4 %					25.15 %
Model parameter							Valuati	on (m)						
Derivation of WACC:			Derivation	of Beta:			Presen	t values 20)27e	1	0			
								al Value			3			
Debt ratio	0.00 %		Financial S	•		1.00		al liabilities			0			
Cost of debt (after tax)	4.2 %		Liquidity (s	hare)		2.00	Pensio	n liabilities			1			
Market return	7.00 %		Cyclicality			2.00	Hybrid				0			
Risk free rate	1.50 %		Transpare	ncy		2.00	-	/ interest			0			
			Others			2.00		val. of inve	estments		0			
							Liquidit	,				No. of sha	()	1.8
WACC	11.40 %		Beta			1.80	Equity	Value		3	9	Value per	ˈshare (E	UR) 21.67

Sensitivity Value per Share (EUR)

	Terminal	Growth								Delta EBIT	-margin					
Beta WACO	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	3.00 %	3.25 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.98 12.4 %	6 21.06	21.09	21.13	21.17	21.21	21.25	21.29	1.98	12.4 %	20.57	20.77	20.97	21.17	21.36	21.56	21.76
1.89 11.9 %	6 21.28	21.32	21.36	21.40	21.45	21.50	21.55	1.89	11.9 %	20.79	20.99	21.20	21.40	21.61	21.81	22.02
1.85 11.7 %	6 21.40	21.44	21.48	21.53	21.58	21.64	21.69	1.85	11.7 %	20.91	21.12	21.32	21.53	21.74	21.95	22.16
1.80 11.4 %	6 21.52	21.57	21.62	21.67	21.72	21.78	21.84	1.80	11.4 %	21.03	21.25	21.46	21.67	21.88	22.09	22.30
1.75 11.2 %	6 21.65	21.70	21.76	21.81	21.87	21.94	22.01	1.75	11.2 %	21.17	21.38	21.60	21.81	22.03	22.25	22.46
1.71 10.9 %	6 21.79	21.85	21.91	21.97	22.03	22.10	22.18	1.71	10.9 %	21.31	21.53	21.75	21.97	22.19	22.41	22.63
1.62 10.4 %	6 22.10	22.16	22.23	22.31	22.38	22.47	22.56	1.62	10.4 %	21.62	21.85	22.08	22.31	22.53	22.76	22.99

• The DCF model bases on the assumption of declining revenues and earnings in the years to come.

• Operating leverage is expected to be burdened by lower sales volumes.

• Main aspect is the changed business model with Hologic (2018 onwards).

• Revenues with clients beside Hologic are not impacted by the transformation process.



Valuation							
	2012	2013	2014	2015	2016e	2017e	2018e
Price / Book	0.5 x	0.8 x	0.9 x	1.1 x	1.4 x	1.4 x	1.4 x
Book value per share ex intangibles	3.44	6.26	8.50	11.10	11.89	12.84	12.31
EV / Sales	0.2 x	0.8 x	1.3 x	0.8 x	1.4 x	1.4 x	1.9 x
EV / EBITDA	0.4 x	2.0 x	3.1 x	2.1 x	4.5 x	4.8 x	13.6 x
EV / EBIT	0.9 x	3.0 x	4.5 x	3.0 x	8.3 x	8.3 x	110.1 x
EV / EBIT adj.*	0.9 x	3.0 x	4.5 x	3.0 x	8.3 x	8.3 x	110.1 x
P / FCF	4.2 x	3.8 x	8.2 x	6.0 x	10.5 x	13.0 x	40.8 x
P/E	5.2 x	6.0 x	7.2 x	5.7 x	17.7 x	19.1 x	162.4 x
P / E adj.*	5.2 x	6.0 x	7.2 x	5.7 x	17.7 x	19.1 x	162.4 x
Dividend Yield	n.a.	n.a.	0.3 %	4.4 %	3.7 %	3.7 %	3.7 %
Free Cash Flow Yield Potential	123.0 %	35.5 %	15.2 %	58.9 %	22.1 %	20.8 %	6.3 %
*Adjustments made for: -							



Consolidated profit & loss


In EUR m	2012	2013	2014	2015	2016e	2017e	2018e
Sales	13.3	14.6	13.1	16.0	14.4	13.9	10.7
Change Sales yoy	-2.4 %	9.4 %	-10.3 %	22.3 %	-9.9 %	-3.9 %	-22.9 %
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Own work capitalised	2.4	1.4	1.2	0.0	0.0	0.0	0.0
Total Sales	15.8	16.0	14.3	16.0	14.4	13.9	10.7
Material Expenses	0.5	0.7	0.6	0.6	0.7	0.7	0.5
Gross profit	15.2	15.3	13.7	15.4	13.7	13.2	10.2
Gross profit margin	114.1 %	104.9 %	104.3 %	96.2 %	95.0 %	95.0 %	95.0 %
Personnel expenses	8.1	7.9	7.0	7.4	7.5	7.5	7.3
Other operating income	1.1	0.5	1.0	1.1	0.4	0.4	0.4
Other operating expenses	2.3	1.9	2.0	2.7	2.0	2.1	1.8
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	6.0	6.1	5.6	6.4	4.6	4.0	1.5
Margin	44.6 %	41.8 %	42.7 %	40.0 %	31.9 %	28.7 %	13.7 %
Depreciation of fixed assets	0.5	0.4	0.2	0.1	0.3	0.3	0.2
EBITA	5.5	5.7	5.4	6.3	4.3	3.7	1.3
Amortisation of intangible assets	2.5	1.9	1.5	1.8	1.8	1.4	1.1
Goodwill amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	3.0	4.1	3.9	4.5	2.5	2.3	0.2
Margin	22.3 %	27.8 %	29.7 %	27.9 %	17.4 %	16.7 %	1.7 %
EBIT adj.	3.0	4.1	3.9	4.5	2.5	2.3	0.2
Interest income	0.1	0.1	0.2	0.2	0.1	0.1	0.1
Interest expenses	0.3	0.1	0.0	0.0	0.0	0.0	0.0
Other financial income (loss)	-0.3	-0.2	0.9	0.3	0.0	0.0	0.0
EBT	2.4	3.8	4.9	5.0	2.6	2.4	0.3
Margin	17.7 %	26.3 %	37.8 %	30.9 %	18.1 %	17.4 %	2.6 %
Total taxes	0.2	0.1	1.2	-1.8	0.0	0.0	0.0
Net income from continuing operations	2.2	3.7	3.7	6.7	2.6	2.4	0.3
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	2.2	3.7	3.7	6.7	2.6	2.4	0.3
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	2.2	3.7	3.7	6.7	2.6	2.4	0.3
Margin	16.2 %	25.4 %	28.4 %	42.1 %	18.1 %	17.4 %	2.6 %
Number of shares, average	1.7	1.7	1.7	1.8	1.8	1.8	1.8
EPS	1.26	2.15	2.16	3.76	1.46	1.35	0.16
EPS adj.	1.26	2.15	2.16	3.76	1.46	1.35	0.16
*Adjustments made for:							

Guidance: 2016e: Sales EUR 14.5-15m; EBIT EUR 2.5-3m

Financial Ratios

2012	2013	2014	2015	2016e	2017e	2018e
73.5 %	68.1 %	66.5 %	60.0 %	68.1 %	71.3 %	86.3 %
n.a.	3.9 x	0.4 x	0.7 x	4.4 x	2.1 x	4.0 x
17.2 x	57.5 x	253.9 x	291.3 x	n.a.	n.a.	n.a.
8.3 %	3.5 %	24.9 %	-36.0 %	0.0 %	0.0 %	0.0 %
0.0 %	0.0 %	1.9 %	25.3 %	65.0 %	70.5 %	603.8 %
113,110	135,185	116,884	142,982	128,847	123,856	95,544
	73.5 % n.a. 17.2 x 8.3 % 0.0 %	73.5 % 68.1 % n.a. 3.9 x 17.2 x 57.5 x 8.3 % 3.5 % 0.0 % 0.0 %	73.5 % 68.1 % 66.5 % n.a. 3.9 x 0.4 x 17.2 x 57.5 x 253.9 x 8.3 % 3.5 % 24.9 % 0.0 % 0.0 % 1.9 %	73.5 % 68.1 % 66.5 % 60.0 % n.a. 3.9 x 0.4 x 0.7 x 17.2 x 57.5 x 253.9 x 291.3 x 8.3 % 3.5 % 24.9 % -36.0 % 0.0 % 0.0 % 1.9 % 25.3 %	73.5 % 68.1 % 66.5 % 60.0 % 68.1 % n.a. 3.9 x 0.4 x 0.7 x 4.4 x 17.2 x 57.5 x 253.9 x 291.3 x n.a. 8.3 % 3.5 % 24.9 % -36.0 % 0.0 % 0.0 % 0.0 % 1.9 % 25.3 % 65.0 %	73.5 % 68.1 % 66.5 % 60.0 % 68.1 % 71.3 % n.a. 3.9 x 0.4 x 0.7 x 4.4 x 2.1 x 17.2 x 57.5 x 253.9 x 291.3 x n.a. n.a. 8.3 % 3.5 % 24.9 % -36.0 % 0.0 % 0.0 % 0.0 % 0.0 % 1.9 % 25.3 % 65.0 % 70.5 %


Sales, EBITDA in EUR m





2012 2013

Performance per Share



75.0 %

50.0 %

25.0 %

0.0 %

-25.0 %

-50.0 %

-75.0 %

COMMENT

5




Consolidated balance sheet


In EUR m	2012	2013	2014	2015	2016e	2017e	2018e
Assets							
Goodwill and other intangible assets	16.8	15.7	15.6	13.9	12.5	11.5	11.0
thereof other intangible assets	6.2	5.0	5.0	3.2	1.8	0.8	0.4
thereof Goodwill	10.6	10.6	10.6	10.6	10.6	10.6	10.6
Property, plant and equipment	0.3	0.5	0.4	0.3	0.1	0.1	0.1
Financial assets	0.3	1.2	1.6	1.7	1.7	1.7	1.7
Other long-term assets	0.0	0.0	0.0	0.9	1.6	1.8	1.8
Fixed assets	17.5	17.4	17.6	16.8	15.9	15.1	14.6
Inventories	0.2	0.0	0.0	0.1	0.1	0.1	0.1
Accounts receivable	3.9	2.0	2.7	2.8	3.2	3.0	2.3
Liquid assets	8.7	9.8	9.3	25.6	26.8	28.5	27.9
Other short-term assets	0.7	4.8	8.7	0.2	0.2	0.2	0.2
Current assets	13.4	16.6	20.7	28.7	30.3	31.8	30.5
Total Assets	30.9	34.0	38.3	45.5	46.2	46.9	45.2
Liabilities and shareholders' equity							
Subscribed capital	1.8	1.8	1.8	1.8	1.8	1.8	1.8
Capital reserve	28.1	9.8	9.8	8.2	8.2	8.2	8.2
Retained earnings	0.0	0.0	0.0	0.4	3.0	5.4	5.7
Other equity components	-7.1	14.9	18.7	23.3	20.7	19.0	17.3
Shareholders' equity	22.8	26.4	30.3	33.7	33.7	34.5	33.0
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	22.8	26.4	30.3	33.7	33.7	34.5	33.0
Provisions	0.8	0.4	0.5	0.6	0.6	0.6	0.6
thereof provisions for pensions and similar obligations	0.0	0.0	0.0	0.6	0.6	0.6	0.6
Financial liabilities (total)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
thereof short-term financial liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	1.1	0.8	0.6	0.6	1.2	1.2	0.9
Other liabilities	6.2	6.3	6.9	10.6	10.6	10.6	10.6
Liabilities	8.1	7.6	8.0	11.8	12.5	12.5	12.2
Total liabilities and shareholders' equity	30.9	34.0	38.3	45.5	46.2	46.9	45.2

Financial Ratios

	2012	2013	2014	2015	2016e	2017e	2018e
Efficiency of Capital Employment							
Operating Assets Turnover	4.1 x	8.4 x	5.2 x	6.1 x	6.5 x	6.9 x	6.6 x
Capital Employed Turnover	0.9 x	0.9 x	0.6 x	1.8 x	1.9 x	2.1 x	1.9 x
ROA	12.4 %	21.3 %	21.1 %	40.0 %	16.5 %	16.0 %	1.9 %
Return on Capital							
ROCE (NOPAT)	17.0 %	25.4 %	15.5 %	40.9 %	30.8 %	32.5 %	2.9 %
ROE	9.9 %	15.1 %	13.1 %	21.0 %	7.8 %	7.1 %	0.8 %
Adj. ROE	9.9 %	15.1 %	13.1 %	21.0 %	7.8 %	7.1 %	0.8 %
Balance sheet quality							
Net Debt	-8.7	-9.8	-9.3	-25.0	-26.1	-27.8	-27.3
Net Financial Debt	-8.7	-9.8	-9.3	-25.6	-26.8	-28.5	-27.9
Net Gearing	-38.1 %	-37.0 %	-30.6 %	-74.1 %	-77.4 %	-80.8 %	-82.6 %
Net Fin. Debt / EBITDA	n.a.						
Book Value / Share	13.2	15.4	17.6	18.8	18.8	19.2	18.5
Book value per share ex intangibles	3.4	6.3	8.5	11.1	11.9	12.8	12.3



Book Value per Share in EUR



COMMENT

Published 29.04.2016

6


Consolidated cash flow statement



In EUR m	2012	2013	2014	2015	2016e	2017e	2018e
Net income	3.1	3.7	3.7	6.7	2.6	2.4	0.3
Depreciation of fixed assets	0.5	0.2	0.2	0.1	0.3	0.3	0.2
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	2.5	1.9	1.5	1.8	1.8	1.4	1.1
Increase/decrease in long-term provisions	-0.4	-0.3	0.0	0.6	0.0	0.0	0.0
Other non-cash income and expenses	0.1	0.6	-0.3	-3.5	0.0	0.0	0.0
Cash Flow	5.7	6.1	5.2	5.8	4.7	4.1	1.6
Increase / decrease in inventory	0.1	0.2	0.0	0.0	0.0	0.0	0.0
Increase / decrease in accounts receivable	0.1	1.0	-0.2	-0.5	-0.4	0.2	0.7
Increase / decrease in accounts payable	-0.6	0.4	-0.1	1.2	0.6	0.0	-0.3
Increase / decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	-0.4	1.6	-0.3	0.8	0.2	0.2	0.4
Net cash provided by operating activities	5.3	7.7	4.8	6.6	4.9	4.3	2.0
Investments in intangible assets	-2.5	-1.5	-1.5	0.0	-0.4	-0.4	-0.6
Investments in property, plant and equipment	-0.1	-0.4	-0.1	-0.1	-0.1	-0.3	-0.2
Payments for acquisitions	-1.4	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.9	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	-3.7	-3.5	8.0	0.0	0.0	0.0
Net cash provided by investing activities	-3.1	-5.6	-5.0	7.9	-0.5	-0.7	-0.8
Change in financial liabilities	0.0	-0.1	0.0	0.0	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	-0.1	-1.7	-1.7	-1.7
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	1.7	0.0	0.0	0.0
Net cash provided by financing activities	0.0	-0.1	0.0	1.6	-1.7	-1.7	-1.7
Change in liquid funds	2.1	2.1	-0.2	16.1	2.7	1.9	-0.5
Effects of exchange-rate changes on cash	-0.1	-0.1	0.2	0.2	0.0	0.0	0.0
Cash and cash equivalent at end of period	8.1	10.1	9.3	25.6	28.4	30.3	29.7

Financial Ratios

	2012	2013	2014	2015	2016e	2017e	2018e
Cash Flow							
FCF	2.7	5.8	3.3	6.5	4.4	3.6	1.2
Free Cash Flow / Sales	20.1 %	40.0 %	25.0 %	40.4 %	30.7 %	26.0 %	10.8 %
Free Cash Flow Potential	3.2	4.4	2.7	8.0	4.6	4.0	1.3
Free Cash Flow / Net Profit	124.3 %	157.5 %	88.1 %	96.0 %	169.5 %	149.2 %	408.8 %
Interest Received / Avg. Cash	0.8 %	1.1 %	2.2 %	0.9 %	0.4 %	0.4 %	0.4 %
Interest Paid / Avg. Debt	14.7 %	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Management of Funds							
Investment ratio	19.5 %	12.7 %	11.9 %	0.7 %	3.4 %	4.9 %	7.6 %
Maint. Capex / Sales	19.1 %	11.3 %	12.9 %	1.4 %	4.2 %	4.3 %	7.5 %
Capex / Dep	87.3 %	92.8 %	92.1 %	6.0 %	23.6 %	40.7 %	63.4 %
Avg. Working Capital / Sales	24.2 %	14.3 %	12.9 %	14.0 %	15.3 %	14.4 %	15.9 %
Trade Debtors / Trade Creditors	341.2 %	255.9 %	472.0 %	501.3 %	266.7 %	250.0 %	255.6 %
Inventory Turnover	3.0 x	n.a.	n.a.	6.1 x	7.2 x	6.9 x	5.4 x
Receivables collection period (days)	107	50	76	63	81	79	78
Payables payment period (days)	780	422	333	330	607	631	614
Cash conversion cycle (Days)	-621	n.a.	n.a.	-260	-545	-567	-531



COMMENT

Published 29.04.2016



LEGAL DISCLAIMER

This research report was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It contains selected information and does not purport to be complete. The report is based on publicly available information and data ("the information") believed to be accurate and complete. Warburg Research GmbH neither does examine the information to be accurate and complete, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these analyses concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this research report, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this document. Provided a research report is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This research report does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this report are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §34B (1) OF THE GERMAN SECURITIES TRADING ACT (WHPG) AND THE ORDINANCE ON THE ANALYSIS OF FINANCIAL INSTRUMENTS (FINANV)

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Potential, Peer Group Comparison or Sum of the Parts Model. The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

In accordance with § 5 (4) of the Ordinance on the Analysis of Financial Instruments (FinAnV) Warburg Research GmbH has implemented additional internal and organisational arrangements to prevent or to deal with conflicts of interest. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg Group.

All prices of financial instruments given in this financial analysis are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin.

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.

3. Any recipient of the Report should effect transactions in the securities discussed in the Report only through J.P.P. Euro-Securities, Inc., Delaware.

4. J.P.P. Euro-Securities, Inc. does not accept or receive any compensation of any kind for the dissemination of the research reports from Warburg.

Reference in accordance with section 34b of the German Securities Trading Act (WpHG) and the Ordinance on the Analysis of Financial Instruments (FinAnV) regarding possible conflicts of interest with the analysed company:

Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the -1research, hold a share of more than 5% of the equity capital of the analysed company. Warburg Research, or an affiliated company, within the last twelve months participated in the management of a consortium -2for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the financial analysis. Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of -3the financial analysis, in a market based on the provision of buy or sell contracts Warburg Research, or an affiliated company, were in the last twelve months bound by a service agreement with the issuers, -4who are themselves or their financial instruments are, subject of the financial analysis, in connection with investment banking business for which a service or a promise of a service emanated. The company compiling the analysis or an affiliated company had reached an agreement on the compilation of the financial -5analysis with the analysed company. Companies affiliated with Warburg Research regularly trade financial instruments of the analysed company or derivatives of -6these. The company preparing the analysis as well as its affiliated companies and employees have other important interests in -7relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company Disclosure		Link to the historical price targets and rating changes (last 12 months)			
MeVis Medical Solutions	3, 5, 6, 7	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A0LBFE4.htm			

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.		
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.		
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.		
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.		

WARBURG RESEARCH GMBH – RESEARCH UNIVERSE BY RATING


Number of stocks	% of Universe
120	64
61	32
6	3
1	1
188	100
	120 61 6 1

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment banking services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	23	77
Hold	7	23
Sell	0	0
Rating suspended	0	0
Total	30	100

PRICE AND RATING HISTORY MEVIS MEDICAL SOLUTIONS AS OF 29.04.2016



The chart has markings if Warburg Research GmbH changed its rating in the last 12 months. Every marking represents the date and closing price on the day of the rating change.



Roland Rapelius Head of Equities

RESEARCH

Michael Heider Head of Research Henner Rüschmeier Head of Research Lucas Boventer Renewables, Internet, Media **Christian Cohrs** Engineering, Logistics Felix Ellmann Software, IT Jörg Philipp Frey Retail, Consumer Goods Harald Hof Medtech **Ulrich Huwald** Health Care, Pharma Thilo Kleibauer Retail, Consumer Goods **Eagert Kuls** Engineering

+49 40 309537-280 mheider@warburg-research.com +49 40 309537-270 hrueschmeier@warburg-research.com +49 40 309537-290 lboventer@warburg-research.com +49 40 309537-175 ccohrs@warburg-research.com +49 40 309537-120 fellmann@warburg-research.com +49 40 309537-258 jfrey@warburg-research.com +49 40 309537-125 hhof@warburg-research.com +49 40 309537-255 uhuwald@warburg-research.com +49 40 309537-257 tkleibauer@warburg-research.com +49 40 309537-256 ekuls@warburg-research.com INSTITUTIONAL EQUITY SALES

+49 40 3282-2673

rrapelius@mmwarburg.com

+49 40 3282-2669 hnass@mmwarburg.com +49 40 3282-2664 kschilling@mmwarburg.com +49 40 3282-2665 tbeckmann@mmwarburg.com +49 69 5050-7411 lboqdanova@mmwarburg.com +49 69 5050-7415 jbuchmueller@mmwarburg.com +49 40 3282-2666 pdontenwill@mmwarburg.com +49 40 3282-2696

mfritsch@mmwarburg.com

Andreas Pläsier Banks, Financial Services Jochen Reichert Telco, Internet, Media J. Moritz Rieser Real Estate Arash Roshan Zamir Cap. Goods, Renewables Malte Schaumann Technology **Oliver Schwarz** Chemicals, Agriculture Marc-René Tonn Automobiles, Car Suppliers **Björn Voss** Steel, Car Suppliers Alexander Wahl Other Andreas Wolf Software, IT

Marie-Therese Grübner France, Switzerland Michael Kriszun United Kingdom Marc Niemann Germany Fabian Roggemann USA Sanjay Oberoi United Kingdom **Juliane Willenbruch** Roadshow/Marketing

+49 40 309537-246 aplaesier@warburg-research.com +49 40 309537-130 jreichert@warburg-research.com +49 40 309537-260 mrieser@warburg-research.com +49 40 309537-155 aroshanzamir@warburg-research.com +49 40 309537-170 mschaumann@warburg-research.com +49 40 309537-250 oschwarz@warburg-research.com +49 40 309537-259 mtonn@warburg-research.com +49 40 309537-254 bvoss@warburg-research.com +49 40 309537-230 awahl@warburg-research.com +49 40 309537-140 awolf@warburg-research.com

> +49 40 3282-2630 maruebner@mmwarbura.com +49 40 3282-2695 mkriszun@mmwarburg.com +49 40 3282-2660 mniemann@mmwarburg.com +49 40 3282-2667 froggemann@mmwarburg.com +49 69 5050-7410 soberoi@mmwarburg.com +49 40 3282-2694 jwillenbruch@mmwarburg.com

SALES TRADING

MACRO RESEARCH

Oliver Merckel Head of Sales Trading Michael Ilgenstein Sales Trading **Bastian Quast** Sales Trading

Holger Nass

Klaus Schilling

Tim Beckmann

Lyubka Bogdanova

Jens Buchmüller

Scandinavia, Austria

Paul Dontenwill

Matthias Fritsch

United Kingdom

USA

United Kingdom, Australia

United Kingdom

Head of Equity Sales, USA

Dep. Head of Equity Sales, GER

+49 40 3282-2634 omerckel@mmwarburg.com +49 40 3282-2700 milgenstein@mmwarburg.com +49 40 3282-2701 bquast@mmwarburg.com

Sales Trading Jan Walter Sales Trading

Jörg Treptow

+49 40 3262-2658 jtreptow@mmwarburg.com +49 40 3262-2662 jwalter@mmwarburg.com

Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com			
Our research can be found under:						
Warburg Research	research.mmwarburg.com/en/index.html	Thomson	www.thomson.com			
Bloomberg	MMWA GO	Reuters	www.knowledge.reuters.com			
FactSet	www.factset.com	Capital IQ	www.capitaliq.com			
For access please contact:						
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703			
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com			

